Monday August 27, 2012 0 comments
FORT COLLINS - The August 2012 edition of the Journal of the American Dental Association includes a nine-page article describing a phase of development of St. Renatus' needle-free dental anesthetic.
The journal manuscript is titled "The cardiovascular effects and pharmacokinetics of intranasal tetracaine plus oxymetazoline: Preliminary findings." It includes data, graphs, methods, statistical analyses, results and conclusions of the Phase 2 Pharmacokinetics study completed in November 2010 at the University of Pennsylvania.
The study determined the safety of the investigative drug in adults, St. Renatus said.
Dr. Elliott Hersh, associate professor of pharmacology oral and maxillofacial surgery at the University of Pennsylvania and principal investigator of the study, submitted the manuscript earlier this year.
The JADA is a source of information for the American Dental Association, which has more than 155,000 members.
"It's a privilege to be included in such a prestigious journal, read by thousands of dentists and other industry professionals around the world,' said Steve Merrick, St. Renatus' CEO. "St. Renatus hopes everyone in the dental profession reads about the development of our investigative drug."
St. Renatus has begun Adult Phase 3 clinical trials at Jean Brown University in Salt Lake City and will soon begin trials at the University of Maryland School of Dentistry.
St. Renatus expects to complete Adult Phase 3 clinical trials by the end of this year.
For more information, visit http://jada.ada.org or www.st.renatus.com.